We are investigating the safety and tolerability of Ziftomenib in patients with relapsed or refractory acute myeloid leukemia. This study aims to understand how well this treatment works alongside other therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed Acute Myeloid Leukemia (AML) occurs when the cancer returns after treatment. It is a serious condition that affects the blood and bone marrow, leading to symptoms such as fatigue, frequent infections, and easy bruising.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
